No products in the cart.
Pre-made Nebacumab benchmark antibody (Whole mAb, anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-925
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody (Pre-made Nebacumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]
| Products Name (INN Index) | Pre-Made Nebacumab Biosimilar, Whole Mab: Anti-Endotoxin (Lipid A, Domain Of Lipopolyaccharide, Lps) [Gram Negative Bacteria] therapeutic antibody |
|---|---|
| INN Name | nebacumab |
| Target | endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria] |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgM – kappa |
| VD LC | IgM – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | CSL?Behring (King of Prussia PA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria] |
| Package |
Previous slide
Next slide
